We are live on ! Find out more
GNOM icon

Global X Genomics & Biotechnology ETF

45 hedge funds and large institutions have $88.3M invested in Global X Genomics & Biotechnology ETF in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

18% more funds holding

Funds holding: 3845 (+7)

16% more capital invested

Capital invested by funds: $76.4M → $88.3M (+$11.8M)

0.41% less ownership

Funds ownership: 9.23%8.82% (-0.41%)

Holders
45
Holders Change
+7
Holders Change %
+18.42%
% of All Funds
0.78%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
17
Reduced
8
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Mirae Asset Global Investments
1
Mirae Asset Global Investments
South Korea
$24.5M -$2.65M -29,878 -11%
PNC Financial Services Group
2
PNC Financial Services Group
Pennsylvania
$23M +$3.16M +35,666 +18%
UBS Group
3
UBS Group
Switzerland
$17.3M -$1.29M -14,565 -8%
MIG
4
McGuire Investment Group
Rhode Island
$6.62M -$27.2K -307 -0.5%
PAG
5
Private Advisor Group
New Jersey
$3.7M +$3.29M +37,144 New
T
6
TRUADVICE
Florida
$3.65M +$683K +7,700 +23%
FTUS
7
Flow Traders U.S.
New York
$1.05M +$469K +5,286 +100%
LPL Financial
8
LPL Financial
California
$840K +$53.9K +608 +8%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$779K -$1.63M -18,417 -70%
OC
10
Oppenheimer & Co
New York
$586K +$522K +5,887 New
OAM
11
Oppenheimer Asset Management
New York
$568K +$106K +1,198 +27%
Bank of America
12
Bank of America
North Carolina
$527K -$525K -5,915 -53%
SPC
13
Sigma Planning Corp
Michigan
$455K +$406K +4,574 New
Citadel Advisors
14
Citadel Advisors
Florida
$390K +$348K +3,919 New
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$383K +$84.6K +954 +33%
CAPTRUST Financial Advisors
16
CAPTRUST Financial Advisors
North Carolina
$347K +$200K +2,250 +183%
FHA
17
Flagship Harbor Advisors
Massachusetts
$309K +$275K +3,103 New
Nomura Asset Management
18
Nomura Asset Management
Japan
$309K
Morgan Stanley
19
Morgan Stanley
New York
$296K -$17.2K -194 -6%
BJL
20
Brighton Jones LLC
Washington
$271K +$798 +9 +0.3%
HSBC Holdings
21
HSBC Holdings
United Kingdom
$249K
Rockefeller Capital Management
22
Rockefeller Capital Management
New York
$238K +$70.9K +800 +50%
CFGS
23
Concourse Financial Group Securities
Alabama
$233K +$1.86K +21 +0.9%
PG
24
Patten Group
Tennessee
$230K +$205K +2,310 New
PWM
25
PRW Wealth Management
Massachusetts
$230K +$205K +2,310 New

GNOM Hedge Fund Activity: Q2 2021 in Review

45 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q2 2021, worth a combined $88.3M — up 16% from $76.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GNOM positions and 5 closed out — a net gain of 7 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Private Advisor Group, opening a new position worth an estimated $3.29M. The largest seller was Mirae Asset Global Investments, cutting an estimated $2.65M.

  • 45 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q2 2021, up from 38 in Q1 2021.
  • Funds reported $88.3M of Global X Genomics & Biotechnology ETF stock for Q2 2021, up 16% quarter-over-quarter.
  • 12 funds opened new Global X Genomics & Biotechnology ETF positions in Q2 2021 and 5 closed out, a net change of +7 holders.
  • The largest Global X Genomics & Biotechnology ETF buyer in Q2 2021 was Private Advisor Group, an estimated $3.29M added.
  • The largest Global X Genomics & Biotechnology ETF seller in Q2 2021 was Mirae Asset Global Investments, an estimated $2.65M sold.

Based on aggregated 13F filings for Q2 2021.